Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02407756
Recruitment Status : Completed
First Posted : April 3, 2015
Results First Posted : October 5, 2020
Last Update Posted : October 5, 2020
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18 years of age) or severe AD (for children ≥6 to <12 years of age).

The secondary objective of the study is to explore the immunogenicity and efficacy of dupilumab in pediatric patients with moderate-to-severe AD (for adolescents ≥12 to <18 years of age) or severe AD (for children ≥6 to <12 years of age).


Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Dupilumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis
Actual Study Start Date : March 31, 2015
Actual Primary Completion Date : March 31, 2016
Actual Study Completion Date : March 31, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Dupilumab

Arm Intervention/treatment
Experimental: Cohort 1
Cohort 1 will receive dupilumab dosing regimen 1
Drug: Dupilumab
Other Name: REGN668(SAR231893)

Experimental: Cohort 2
Cohort 2 will receive dupilumab dosing regimen 2
Drug: Dupilumab
Other Name: REGN668(SAR231893)




Primary Outcome Measures :
  1. Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration [ Time Frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50 ]
    Peak dupilumab concentration in serum following single dose administration. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

  2. PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration [ Time Frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50 ]
    Mean AUC estimates were calculated using mean concentration data at each time point, using a non-compartmental approach (NCA). Calculated AUClast (computed from time zero to the time of the last positive concentration) are presented. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

  3. PK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose [ Time Frame: Pre-dose on Day 71 and Day 85 ]
    Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of study drug.


Secondary Outcome Measures :
  1. Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12 [ Time Frame: Baseline to Week 12 (one week after last dose) ]
    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD. Analysis was performed on safety analysis set (SAF) that included all subjects who received any study drug. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by last observation carried forward (LOCF).

  2. Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12 [ Time Frame: Baseline to Week 12 (one week after last dose) ]
    SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis ("Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". Dermatology (Basel) 186 (1): 23-31. 1993). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 [absent disease] to 103 [severe disease]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

  3. Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12 [ Time Frame: Baseline to Week 12 (one week after last dose) ]
    Pruritus NRS scale is an assessment tool that is used to report the intensity of subject's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Subjects were asked the following question: how would a subject rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

  4. Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12 [ Time Frame: Week 12 ]
    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Analysis was performed on SAF. Subjects with rescue treatment usage during the Part B period were specified as non-responders from the time the rescue was used.

  5. Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12 [ Time Frame: Baseline to Week 12 ]
    Body surface area affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]). It was reported as a percentage of all major body sections combined. Analysis was performed on SAF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Male or female patients ≥6 to <18 years of age with a diagnosis of 1. Atopic Dermatitis whose disease cannot be adequately controlled with topical medications
  2. Minimum disease severity, as defined by Investigator's Global Assessment (IGA)

    1. IGA = 3 or 4 in adolescents ≥12 to <18 year of age
    2. IGA = 4 in children ≥6 to <12 years of age

Key Exclusion Criteria:

  1. Recent treatment (within specific time windows before the baseline visit) with systemic immunosuppressive agents for eg. Systemic corticosteroids, live (attenuated) vaccines and other investigational drugs including biologics
  2. History of any of the following infections:

    1. Any systemic infection requiring treatment within 4 weeks before the baseline visit
    2. Superficial skin infections within 1 week before the baseline visit
    3. Known history of HIV infection
    4. History of seropositivity to hepatitis B or C screening tests
    5. History of clinical endoparasitosis (ie, helminthic infection) within 12 months before the baseline visit, or high risk of helminthic infection, unless subsequent medical assessments (e.g. stool exam, blood tests, etc.) have ruled out the possibility of parasite infection/infestation
  3. History of malignancy within 5 years before the baseline visit
  4. Persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) more than 3 times the upper limit of normal (ULN) during the screening period
  5. Presence of any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study
  6. Presence of skin comorbidities that may interfere with study assessments
  7. Females patients who are pregnant or breastfeeding
  8. Female patients who are of reproductive potential and are sexually active, who are unwilling to use adequate methods of contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02407756


Locations
Layout table for location information
Canada, Ontario
Markham, Ontario, Canada
Peterborough, Ontario, Canada
Waterloo, Ontario, Canada
Windsor, Ontario, Canada
Czechia
Kutna Hora, Czechia
Prague, Czechia
Germany
Dresden, Germany
Frankfurt, Germany
Gera, Germany
Hamburg, Germany
Kiel, Germany
Luebeck, Germany
Muenster, Germany
Munich, Germany
Tuebingen, Germany
Hungary
Kaposvar, Hungary
Miskolc, Hungary
Szeged, Hungary
Szolnok, Hungary
Poland
Katowice, Poland
Krakow, Poland
Lodz, Poland
Warszawa, Poland
Wroclaw, Poland
United Kingdom
Manchester, United Kingdom
Sheffield, United Kingdom
Sponsors and Collaborators
Regeneron Pharmaceuticals
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02407756    
Other Study ID Numbers: R668-AD-1412
First Posted: April 3, 2015    Key Record Dates
Results First Posted: October 5, 2020
Last Update Posted: October 5, 2020
Last Verified: September 2020
Keywords provided by Regeneron Pharmaceuticals:
Eczema
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases